We identified 19 persons with B-cell chronic lymphocytic leukemia (CLL) who received genetically identical twin blood cell or bone marrow transplants after high-dose conditioning. Ten are alive (eight disease-free) with a median follow-up of 89 months (range, 31-171 months); 5-year relapse rate was 50% (95% confidence interval (CI), 26-73%). Estimated 5-year survival and disease-free survival were 61% (95% CI, 37-82%) and 45% (95% CI, 23-68%). In two of four patients tested at 12 and 21 months by polymerase chain reaction no evidence of residual CLL was detected post-transplant. In one recipient who relapsed at 6 years, molecular studies showed a different CLL clone from that detected pretransplant. This clone was subsequently identified in the donor suggesting transfer of occult leukemia at the time of transplant. Genetically identical twin transplants can result in long-term disease-free survival and molecular remissions, these data suggest the potential for CLL control in the absence of allogeneic graft-versus-leukemia effect. The case of leukemia transfer indicates the need for careful evaluation of donors prior to graft collection.
Introduction
Studies of genetically identical twin blood cell and bone marrow transplants can provide unique insights into disease mechanisms and therapies. Graft rejection cannot occur and graft-versus-host disease (GVHD)-related or other allogeneic antileukemia effects are absent. In this setting there is no prior graft exposure to cytotoxic therapy and there should be no cancer cells contaminating the graft that could be transferred to the recipient. Because genetically-identical twin transplants are rare, studies by large international registries are needed; several are reported. [1] [2] [3] [4] [5] Rates of leukemia relapse in twins are substantially higher than in allograft recipients including those with and without GvHD. 6 These data suggest allogeneic immune-mediated graft-versus-leukemia (GVL) effect operates after most allotransplants for leukemia. In contrast, leukemiarelapse risk is generally higher after autotransplants than after twin transplants 1, 2, 7 suggesting leukemia contamination of the graft. 3, 8 There is good evidence of a GVL effect after allotransplants for B-cell chronic lymphocytic leukemia (CLL) where an important proportion of patients achieve durable clinical and molecular remissions. [9] [10] [11] [12] [13] In contrast, autotransplants have high rates of relapse.
14-16 Here, we report 19 patients with CLL who received genetically identical twin transplants. Our objectives were to determine clinical outcomes.
Materials and methods
Nineteen patients with CLL were transplanted between 1980 and 2001 and reported to the Center for International Blood and Marrow Transplantation Research (CIBMTR), (n ¼ 15), the Fred Hutchinson Cancer Research Center (n ¼ 3) or the European Group for Blood and Marrow Transplantation (n ¼ 1). Data were prospectively collected using the standard CIBMTR core forms, additional Supplementary Information was requested from transplant centers at the time of study using predesigned CLLspecific data collection forms available at: http://www.cibmtr.org/DATA/report_forms_idx.html. Genetically identical twin state was confirmed independently at each site by history, RBCantigen and HLA-typing and/or by DNA-polymorphism analyses. No subject received GVHD prophylaxis. Complementarity-determining region (CDR)III of IgH-gene PCR amplification was performed on pretransplant CLL samples in four patients where both pre-and post-transplant cell samples could be obtained. CLL-specific primer and probe were generated for each patient to monitor minimal residual disease (MRD) post-transplant. 17 
Results and discussion
Patients received genetically identical twin bone marrow (n ¼ 11) or blood cell (n ¼ 8) transplants after high-dose conditioning. Median age was 51 years (range, 37-68 years). The median interval from diagnosis to transplant was 27 months (5-171 months). Characteristics of the patients are shown in Table 1 . At the time of transplant eight had Rai stage-3/4, five had 450 Â 10 9 l À1 lymphocytes, 10 received X3 prior chemotherapy sequences and a variety of agents in the attempt to control the disease, eight had prior fludarabine, five were in complete remission (CR) at some time prior to transplant. Eighteen patients engrafted and 13 achieved complete remission (NCI criteria). 18 The median time to CR was 3 months (range, 1-5 months). The probability of 100 day survival was 89% (95% CI, 72-99%). Ten patients are alive post-transplant (eight leukemia-free) with median follow-up of 89 months (range 31-171 months) post-transplant. Six patients never achieved CR and four relapsed after achieving CR. The 5-year cumulative incidence of relapse was 50% (95% CI, 26-73%). The estimated 5-year overall and disease-free survival rates were 61% (37-82%) and 45% (23-68%) respectively ( Figure 1 ). All five patients who had CR at some point before transplant are alive (four in CR). One subject died of interstitial pneumonitis and eight of recurrent leukemia. The 5-year treatment-related mortality (TRM) was 5% (0-20%).
In four patients in whom both pre-and post-transplant cell samples were obtained we used a highly sensitive (one cancer cell detected among 10 À4 -10 À5 normal cells) PCR method to study blood (n ¼ 2) or bone marrow (n ¼ 2) for the leukemiaspecific IgH CDRIII gene to assess MRD post-transplant. IgH CDRIII was PCR amplified in pretransplant CLL samples. Sequence data for the primers and probes are summarized in the Supplementary Figure S1 . No signal was detected in two patients (UPNs 11 and 17) when tested 21 and 12 months posttransplant (Table 1) . A weak clonal signal was identified in UPN 13 at 64 months post-transplant. These three patients are in continuous CR at 110, 37 and 86 months post-transplant, respectively. A fourth subject (UPN 7) relapsed 6 years after transplant. A strong clonal signal was detected at 10 years follow-up but the CDRIII sequence was confirmed to be different from that present pretransplant. It was subsequently discovered that the donor developed CLL post donation and had an identical signal to the one detected in recipient's relapse leukemia cells strongly suggesting donor origin of the posttransplant leukemia recurrence in the recipient. Sequence comparison between the original and newly developed CLL is shown in Supplementary Figure S2 ).
Although most of these patients could not be characterized by using modern biological prognostic factors such as FISH karyotype or mutational status and did not receive therapies such as monoclonal antibodies, eight out of ten surviving patients remain disease-free for 32-171 months (median 88 months) indicating very good leukemia control. The 5-year leukemia-relapse rate of 50% seems higher than observed in similar patients receiving allotransplants but not necessarily different than in similar patients receiving autotransplants. 11, 14, 15, 19 These findings support GVL effect of allotransplants in CLL. Leukemia cells in the graft may contribute to A, adriamycin; B, bleomycin; BM, bone marrow; C, cyclophosphamide; Cb, chlorambucil; CLL, chronic lymphocytic leukemia; CR, complete remission achieved at any time prior to transplant; D, dexamethasone; F, fludarabine; HCT, hematopoietic cell transplant; If, interferon-a; M, methylprednisolone; mo, number of months; MRD, minimal residual disease; NA, not assessable; Number of prior treatments, number of chemotherapy sequences delivered to control the disease; each sequence was separated with periods of observation, P, prednisone; PD, persistent disease; Rai stage, Rai stage at the time of transplantation; TBI, total-body-irradiation; V, vincristine; VP, etoposide; F ¼ data not available.
a After donation the twin donor was diagnosed with CLL. Molecular analysis of the donor CLL showed a clone that was identical to the recipient's relapse clone indicating leukemia transmission from the donor.
Genetically identical twin transplantation SZ Pavletic et al relapse after autotransplants. It is possible that a newly regenerated immune system in twins is able to suppress or eliminate minimal residual CLL cells in the post-transplant setting.
Data from molecular analyses of subject UPN 7 and his donor (see above) strongly suggest transmission of CLL through the graft. Although in general population most twins are not concordant for clinical diagnosis of leukemia or lymphoma, 20 considerable data support familial clustering of CLL. 21 The leukemic transforming events in CLL seem to occur later in life and even in identical twins result in genotypically distinct malignant cells. 22 Two studies report the increased existence of monoclonal B-cell lymphocytosis (MBL) in unaffected firstdegree relatives of persons with familial CLL. The 15-18% 23, 24 prevalence of MBL in this setting contrasts with a 0.1-5% prevalence in normals. 25, 26 Whether MBL is a precursor state to CLL or other lymphoproliferative disorders is unknown. The presence of leukemia clone in the donor of UPN 7 who relapsed with CLL supports the notion of a preleukemia phase. Transfer of leukemia by an allotransplant is reported in several leukemias including three cases of CLL. 27, 28 Sala-Torra et al. 28 suggested two mechanisms of donor-derived leukemia in the recipient. The first is the transfer of preleukemia cells from donor to recipient, most likely the scenario in our patient UPN 7. The second is the development of leukemia in normal donor stem cells. These leukemia transfer cases at the time of transplant indicate the need for careful evaluation of donors prior to graft collection, 27, 29 particularly if they are relatives, older, or have positive family history of CLL.
In summary, this study shows favorable outcomes for genetically identical twin transplants for CLL with the achievement of durable clinical remissions and also molecular remissions. Comparisons to allotransplants suggest a GVL effect in CLL, whether from GVHD, allogeneic non-GVHD effects, leukemia-specific or some combination thereof. Comparison to autotransplants suggests leukemia contamination of the graft may contribute to relapse after autotransplants. As some patients achieve long-term disease control of their CLL following a syngeneic transplant; further study of innovative therapeutic approaches like high-dose therapy in a non-transplant setting or the possible use of immune modulations are warranted. 
